Search results
434 Results for 'Drug Development'
- Technologies (30)
- Collaborations (7)
- Team (0)
- News (310)
- Pages (0)
- Multimedia (87)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 30
-
DNA Nanoswitch Calipers for Single-Molecule Proteomics
DNA nanoswitch calipers are a first-of-their-kind research tool that leverage DNA’s unique molecular qualities to study post-translational modifications on proteins to unlock a new frontier of medicine. -
Ropirio: Novel Treatments Targeting the Lymphatic System
Ropirio is commercializing the world’s first drug that directly targets and reactivates lymph vessels, a portfolio of other lymph-targeting small molecules, and a preclinical platform for discovering more. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
DNA Nanostructures for Drug Delivery
Researchers at the Wyss Institute have developed two methods for building arbitrarily shaped nanostructures using DNA, with a focus on translating the technology towards nanofabrication and drug delivery applications. One proprietary nanofabrication technique, called “DNA-brick self-assembly,” uses short, synthetic strands of DNA that work like interlocking Lego® bricks. It capitalizes on the ability to program... -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Lactation Biologics: Increasing Milk Production for Healthier Babies
Lactation Biologics is developing a long-lasting, self-injectable treatment to help nursing mothers feed their babies naturally, helping them get the best nutrition possible in the face of climate disasters and supply chain disruptions.
Collaborations 7
-
Nucleic Acid Delivery Consortium
An academic-industry consortium focused on the challenge of delivering nucleic acid-based therapies to specific target organs, tissues, and cells. -
Brain Targeted Therapeutic Collaboration
Combine our shuttles with your drugs to create new brain targeted therapeutics for patients. -
Brain Shuttle Research Sponsorship & Licensing
Enabling brain-targeted drug development through non-exclusive licensing and pre-competitive research sponsorship. -
Bridging the Funding Gap for Brain Therapeutics
A unique opportunity to help develop a new generation of brain targeted drugs -
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration.
News 310
Multimedia 87
-
Video/AnimationCutting to the Case: Don IngberDon Ingber, M.D., Ph.D., is the Founding Director of Harvard University’s Wyss Institute for Biologically Inspired Engineering and a pioneer of organ-on-a-chip technology. In this episode of Cutting to the Case, Ingber and host Cameron Sabet discuss how he helped create organs-on-chips, what these systems can teach us that traditional models cannot, and how biologically... -
Audio/PodcastBuying time: A medical breakthrough in stroke treatmentWhen a stroke strikes, every minute matters. Science has traditionally approached stroke as a race against time. But rather than racing faster, what if we could instead slow the damage down? Join host Shahni Wellington as she explores groundbreaking research aimed at buying more time for stroke patients, particularly those in rural and regional communities.... -
Audio/PodcastNext-Gen Toxicology: Inside the Organ Chip Revolution with Donald IngberIn this episode of ToxChats, hosts Lauren Walker and Sarah Benjamin sit down with the groundbreaking Donald Ingber—visionary scientist, engineer, and Founding Director of the Wyss Institute. Ingber shares how his unique path through medicine, biology, and design converged to spark breakthroughs such as human Organ Chips—systems that are redefining toxicology, drug development, and disease...
-
Video/AnimationCure ALD – Behind the Research | Alex LeNail – Safer Gene TherapyLearn about Wyss Postdoctoral Fellow Alex LeNail‘s background and how he plans to develop a safer gene therapy for ALD (adrenoleukodystrophy) patients. If successful, this could go to clinical trials and give families hope for a cure. This video series tells the story of the scientists behind the breakthroughs, and why community-driven fundraising is the... -
Audio/PodcastJames Collins: Doing Good Science with an Underdog Spirit – The Pulse PodcastJames J. Collins is a founding Core Faculty member at the Wyss Institute and the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. Jim serves as a director at the MIT Jameel Clinic, a member of the Harvard-MIT Health Sciences & Technology Faculty, and a member of the Broad... -
Audio/PodcastBrain Shuttles: A New Path Into the Brain with James Gorman of the Wyss InstituteThe host of Business Trip, Matias Serebrinsky, interviews Wyss Senior Director of Translational R&D James (Jim) Gorman, M.D., Ph.D. Jim is a Principal Investigator of the Wyss Institute Brain Targeting Program (BTP). He leads a team developing new approaches to transport drugs through the blood-brain barrier (BBB) into the central nervous system. In this episode,...